Royalty Pharma Plc (NASDAQ: RPRX)
Royalty Pharma Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Royalty Pharma Plc Company Info
Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
News & Analysis
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months
Analysts are quite bullish about these beaten-down stocks.
2 Dividend Stocks Wall Street Thinks Can Rise by 50%
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit.
Valuation
Earnings Transcripts
Royalty Pharma plc (RPRX) Q2 2022 Earnings Call Transcript
RPRX earnings call for the period ending June 30, 2022.
Royalty Pharma plc (RPRX) Q1 2022 Earnings Call Transcript
RPRX earnings call for the period ending March 31, 2022.
Royalty Pharma plc (RPRX) Q4 2021 Earnings Call Transcript
RPRX earnings call for the period ending December 31, 2021.
Royal Pharma (RPRX) Q3 2021 Earnings Call Transcript
RPRX earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.